Welcome to the mRNA- Based Therapeutics Summit Europe: Expanding the Therapeutic Applicability of mRNA- Based Drugs
Built with biopharmaceutical industry insights, this in-person conference will bring together key opinion leaders from Europe and the rest of the world to delve deep into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity, delivery & efficacy for immuno-oncology, infectious diseases and beyond.
With 20+ pioneering large pharma, biotech and academic experts who are shaping the landscape of mRNA- based therapeutics for the scientific community world-wide, hear how they address the major challenges facing the industry.
Optimise the Efficacy, Cell- & Tissue- Specificity & Translatability of Your mRNA- Based Pipeline
With the limitless opportunity of mRNA- based Therapeutics across different modalities, consider the challenges of efficacy and improve cell- & tissue- specificity with expert insights from Professor Drew Weissman, Strand Therapeutics & Chalmers University of Technology
Explore Applications of mRNA- Based Therapeutics Beyond Infectious Diseases
From immune-oncology to rare and autoimmune diseases, dive into emerging applications and potential challenges of mRNA- based vaccines and therapeutics beyond infectious diseases with case studies from Moderna, BioNTech & Ethris
Navigate New & Emerging Delivery Technologies for mRNA- Based Therapeutics
Take yourself to the forefront of mRNA delivery system development, from structure through to administration with insights from BioNTech, Johnson & Johnson & 20Med Therapeutics
Strategise Your Scalable & Global mRNA-Based Vaccine Development
With the global outreach of mRNA- based vaccines, scalability is a major hurdle. Hear the latest technological advances and regulatory standards in mRNA- based vaccine and therapeutic landscape from Sanofi, Ziphius Vaccines & Arcturus Therapeutics
Tune into How Companies are Differentiating Their Pipelines Beyond mRNA- Based Vaccines
With the success of mRNA- based vaccines fulfilling novel technologies and therapies such as mRNA- based protein replacement, hear from companies like Strand Therapeutics, Turn Biotechnologies & Orna Therapeutics on the emerging strategies that will enable innovation in the field
Expert Speakers Include:
Senior VP - RNA Biochemistry & Manufacturing
Johnson & Johnson
Professor - Vaccine Research
University of Pennsylvania, Perelman School of Medicine
Health & Safety
The health, safety and well-being of our community remains our highest priority. Therefore, all attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours the event*.
For further information around Health and Safety onsite, please visit our FAQ here.
*Please note, this is subject to change at any time without prior notice.
Group Discounts Available
Maximize value for money using special team discounts:
10% discount - 3 delegates
15% discount - 4 delegates
20% discount - 5+ delegates